Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (March 2020)
20 slides from Imagion Biosystems's investor presentation, Mar 2, 2020
Slide 1: MagSense Technology
MagSense™ Technology Early detection of cancer through targeted imaging ASX:IBX www.imagionbiosystems.com
Slide 2: Disclaimer
DISCLAIMER This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire
Slide 3: Imagion Biosystems At-a-Glance
I M A G I O N B I O S Y S T E M S AT - A - G L A N C E New medical imaging technologies for the early detection of cancer Imagion Biosystems • Innovative medical imaging using magnetic nanoparticles to identify and ASX:IBX stage cancer early Australian Medical Device Company developing bio-safe medi
Slide 4: A Growing Global Health Problem
A G R O W I N G G L O B A L H E A LT H P R O B L E M 1 in 3 people are affected by cancer $100B CANCER DIAGNOSTICS MARKET Each year cancer kills 9 $30,000 million people $26,044 $25,000 $100B spent annually to $20,136 $20,000 diagnose or detect Millions (USD) $15,541 cancer, yet cancer $15,000 conti
Slide 5: Clear Unmet Medical Need
CLEAR UNMET MEDICAL NEED 50 years since last new imaging technology was introduced X-RAY ULTRASOUND MAGNETIC RESONANCE COMPUTED POSITRON EMISSION TOMOGRAPHY (MAMMOGRAPHY) 1956 (MRI) TOMOGRAPHY (CT) (PET) 1913 1971 1972 1973 • Best used for • Inexpensive and fast • Best for imaging soft • Better for
Slide 6: Medical Imaging Breakthrough
MEDICAL IMAGING BREAKTHROUGH MagSense™ Technology will transform cancer diagnosis • Non-invasive – a safe and non-surgical solution to detect cancer • No radioactivity - uses bio-safe magnetic nanoparticles to “tag” cancer cells • Platform technology – can be used for many cancers as well as other d
Slide 7: Improving Outcomes
IMPROVING OUTCOMES Better sensitivity could mean earlier detection MagSense™ technology is expected to have sensitivity comparable to PET without use of radioactivity, making it better for routine use in early detection and resulting in more successful treatments and patient outcomes. SURVIVAL RATE
Slide 8: Transformative Medical Imaging
T R A N S F O R M AT I V E F O R M E D I C A L I M A G I N G Designated by FDA as a “Breakthrough Device” The MagSense™ HER2 Metastatic Breast Cancer Test • Works within current standard cancer diagnosis and staging protocols. • Replaces current non-functional imaging such as MRI or ultrasound used
Slide 9: Broad Commercial Applicability
BROAD COMMERCIAL APPLICABILITY Can be used for many types of cancer and at multiple stages of diagnosis MAGSENSE NANOPARTICLES MULTIPLE CLINICAL TARGETS • Are bio-functionalized to ensure high specificity for targeting different types of cancers, or other diseases. • Can be used at multiple stages i
Slide 10: Compelling Business Model
COMPELLING BUSINESS MODEL Proprietary consumable drives growth & profitability PRINTER / INK ONE INSTRUMENT MANY TESTS REVENUE MODEL 35% capacity utilization HER2 Breast Ovarian A$2.2 million annual Cancer Cancer revenue per instrument Prostate Lung Cancer Cancer Revenue through US$500K Capital US$1
Slide 11: Investment Rationale
I N V E S T M E N T R AT I O N A L E Strategic plan provides path to future products & shareholder value STAGING TUMOR MRI TREATMENT DOCTORS DETECTION & BREAST CANCER DETECTION CONTRAST MONITORING OFFICE THERAPY Reduce unnecessary Breast, prostate, lung Safer alternative to Monitor tumor size Hand-h
Slide 12: Milestones and Valuation Drivers
M I L E S T O N E S A N D V A L U AT I O N D R I V E R S Indicative development timeline and key inflection points* Milestones Achieved in 2018-19 • First-in-human study in FY2020 – study duration expected to be 3-6 months. • First human data key validation point, paves way for discussion with comme
Slide 13: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD Collective expertise in oncology, medical imaging, nanotechnology, clinical trial design World class scientific collaborations & partnerships: DR JOHN HAZLE PROF LISA HORVARTH DR ROBERT IVKOV SCIENTIFIC ADVISORY BOARD CHAIR • Director, Department of • Expertise in radiation
Slide 14: Experienced Board & Management
EXPERIENCED BOARD & MANAGEMENT Commercially focused team with deep industry & clinical experience ROBERT PROULX OLIVER STEINBACH MICHAEL HARSH DAVID LUDVIGSON BRONWYN LE GRICE CHAIRMAN & CEO VP CLINICAL & NON EXEC DIRECTOR NON EXEC DIRECTOR NON EXEC DIRECTOR REGULATORY AFFAIRS • 35 years in pharma,
Slide 15: Capital Structure
C A P I TA L S T R U C T U R E No debt, one class of common stock Ordinary shares on issue 511.28M* Share price – Last 12 months Share price (26 Feb 2020) 0.029 $0.06 Receipt of Average daily volume 7.2M “Breakthrough Device” $0.05 status by the US FDA Market capitalization 14.83M (26 Feb 2020) $0.0
Slide 16: Investment Highlights
INVESTMENT HIGHLIGHTS LARGE OPPORTUNITY UNIQUE TECHNOLOGY $100B cancer diagnostic market New form of medical imaging Growing 7% annually Molecularly specific & non-invasive Medical imaging commands largest share More sensitive than current methods Huge medical need for early diagnosis Protected by e
Slide 17: Appendix
Contact: www.imagionbiosystems.com Appendix info@imagionbio.com ASX: IBX
Slide 18: How It Works
HOW IT WORKS Bio-safe magnetic nanoparticles are attracted to the tumor and detected • Nanoparticles, specific for the cancer, bind to tumor cells. • Nanoparticles demagnetize or “relax” after exposure to a low magnetic field. • Nanoparticles attached to cancer cells “relax” more slowly than particl
Slide 19: Pre-Clinical Research
PRE-CLINICAL RESEARCH Product performance verified in pre-clinical models SPECIFICITY • In vitro cell based studies confirm specificity for HER2 expressing breast cancer cells. • Animal studies confirm in vivo selectivity for HER2 expressing breast cancer tumours. SENSITIVITY • In vitro cell based s
Slide 20: Improving MRI Diagnostic Utility
IMPROVING MRI DIAGNOSTIC UTILITY Additional commercial opportunity as an MRI contrast agent • MagSense™ iron oxide nanoparticles generate T2* MRI T1 T2 T2* contrast even at low concentrations. • Targeted nanoparticles would change MRI from identifying a region of interest to imaging for specific tum
Imagion Biosystems — Investor Presentation (March 2020) on 6ix